Business Context and Reporting Period
This Form 8-K was filed by Protagonist Therapeutics, Inc. on February 3, 2017. The report discloses compensatory arrangements for the Company's principal executive officers and named executive officers, specifically regarding 2016 bonus payments and 2017 salary and target bonus structures approved by the Compensation Committee.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation:
| Executive Officer | 2016 Bonus | 2017 Salary | 2017 Target Bonus |
|---|---|---|---|
| Dinesh V. Patel, Ph.D. (CEO) | $160,000 | $475,000 | 50% |
| David Y. Liu, Ph.D. (CSO) | $93,000 | $357,000 | 40% |
| Tom O'Neil (CFO) | $72,063 | $300,000 | 35% |
| William Hodder (SVP Corporate Dev) | $63,375 | $280,000 | 35% |
Material Changes
The filing details the approval of 2016 cash bonuses and the establishment of 2017 annual salaries (effective retroactively to January 1, 2017) and target performance bonus percentages. No comparative financial performance data or material changes to the Company's operational status are provided in this document.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The document is strictly limited to the disclosure of executive compensation arrangements.
Investor Verification Checklist
- Verify the total cash outflow for 2016 bonuses ($388,438) and the annualized salary commitment for 2017 ($1,412,000) for the named executives.
- Confirm the retroactive effective date of the 2017 salary adjustments (January 1, 2017).
- Review the Company's most recent 10-K or 10-Q for context on overall cash burn and liquidity, as this 8-K does not provide company-wide financial metrics.